Trial Profile
Phase I Study of the Oral PI3kinase Inhibitor BKM120 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or Recurrent High Grade Serous Ovarian Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2022
Price :
$35
*
At a glance
- Drugs Alpelisib (Primary) ; Buparlisib (Primary) ; Olaparib (Primary)
- Indications Advanced breast cancer; Ovarian cancer; Triple negative breast cancer
- Focus Adverse reactions
- 01 Sep 2022 Pooled analysis assessing HRD data detected by panel sequencing obtained as part of routine clinical care published in the Clinical Cancer Research.
- 11 Feb 2022 Results (n=17) published in the Clinical Cancer Research
- 21 May 2021 Results assessing correlative analysis of Sig3 as predictor of response by using data from this study presented at the 112th Annual Meeting of the American Association for Cancer Research